New Post Public Reply Private Reply Replies (0) Message Board ← Newer Older → News Desk 2022 Jan 29, 2019 at 9:45 AM 19 Processa Pharmaceuticals, Inc. (PCSA: OTCQB) | PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA Newer Older
